¼«ËÙÁùºÏ²Ê

Nathan Blue
( out of 12 reviews )

Nathan Blue, MD, MSCI

Languages spoken: English, Spanish

Clinical Locations

Greenwood Health Center

Midvale
801-213-9400

Sugar House Health Center

Salt Lake City
801-581-2000

University of ¼«ËÙÁùºÏ²Ê Hospital

University Maternal Fetal Medicine, Area E
Salt Lake City
801-213-2995

  • As a dedicated and compassionate provider, Dr. Nathan Blue is a high-risk pregnancy specialist. Dr. Blue has a clinical interest in preeclampsia/hypertension in pregnancy, fetal growth restriction, stillbirth, and complications related to maternal and fetal health. For all his patients, he provides comprehensive prenatal care for individuals with complex pregnancies.

    Dr. Blue is currently accepting new patients. To make an appointment, please call the Women’s Health Center at 801-213-2995 for more information.

    Dr. Blue earned his medical degree from Loma Linda University School of Medicine in California. He completed his Obstetrics & Gynecology residency at Los Angeles General Medical Center, where he developed a strong passion for research and a commitment to serving underserved patients. Following this, he pursued a fellowship at the University of New Mexico and served as a Women's Reproductive Health Research (WRHR) K12 scholar at ¼«ËÙÁùºÏ²Ê from 2018 to 2022.

    His ongoing NIH-funded research aims to use AI to create personalized prenatal risk assessment tools, helping families and health care providers make informed decisions in uncertain situations. Dr. Blue has researched critical topics such as preeclampsia, preterm birth, stillbirth, and fetal growth restriction.

    As a fluent Spanish speaker, Dr. Blue enjoys working with the Spanish-speaking communities.

    Specialties

    Board Certification

    American Board of Obstetrics & Gynecology
    American Board of Obstetrics & Gynecology (Sub: Maternal-Fetal Medicine)

    Patient Rating

    5.0 /5
    ( out of 12 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    July 22, 2024
    SUGAR HOUSE HEALTH CENTER

    Dr. Blue always includes me like I'm part of the care team. I feel that he respects where I'm coming from, and always takes the time to answer my questions and explain my options. I couldn't imagine a better doc for me during this wild ride.

    October 13, 2023
    SUGAR HOUSE HEALTH CENTER

    He is kind and listened to all of our concerns. He took time to explain things and was caring.

    August 12, 2023
    SUGAR HOUSE HEALTH CENTER

    Dr. Blue is caring, attentive, and easygoing all in one. We have a high risk pregnancy and he listens to and addresses our concerns, answers ALL questions no matter how big or small, and takes care to explain/weigh options with us.

    August 03, 2023
    SUGAR HOUSE HEALTH CENTER

    Excellent treatment from Dr. Blue. On top of offering his expert opinion on pregnancy matters, he offered pretty solid psychological counseling. Very good at listening and validating my emotions.

    April 19, 2023
    SUGAR HOUSE HEALTH CENTER

    Dr. Blue is the first MD to really listen to me and talk to me about my concerns. You can tell that he is passionate about womens health and every patient he treats. I left his office feeling much more confident and a true partner in my own care.

    December 20, 2022
    SUGAR HOUSE HEALTH CENTER

    Nathan made me feel very supported as well as helped me understand more about the process.

    October 06, 2022
    SUGAR HOUSE HEALTH CENTER

    Dr. Blue is awesome! It was worth the wait to get to chat with him. Very knowledgeable and you can tell he really enjoys the work he does. I learned a lot with just one appointment with him. He is down to earth and very approachable. I'd definitely recommend him to friends and family.

    September 29, 2022
    SUGAR HOUSE HEALTH CENTER

    I was surprised and appreciative that Dr. Blue was willing to take so much time with me to thoroughly answer questions during my first visit.

    September 26, 2022
    SUGAR HOUSE HEALTH CENTER

    Dr. Blue is always inquisitive about my experience and welcomes questions. He has been very thorough in explaining my condition and I really like his approach, it's very comprehensive.

  • As a dedicated and compassionate provider, Dr. Nathan Blue is a high-risk pregnancy specialist. Dr. Blue has a clinical interest in preeclampsia/hypertension in pregnancy, fetal growth restriction, stillbirth, and complications related to maternal and fetal health. For all his patients, he provides comprehensive prenatal care for individuals with complex pregnancies.

    Dr. Blue is currently accepting new patients. To make an appointment, please call the Women’s Health Center at 801-213-2995 for more information.

    Dr. Blue earned his medical degree from Loma Linda University School of Medicine in California. He completed his Obstetrics & Gynecology residency at Los Angeles General Medical Center, where he developed a strong passion for research and a commitment to serving underserved patients. Following this, he pursued a fellowship at the University of New Mexico and served as a Women's Reproductive Health Research (WRHR) K12 scholar at ¼«ËÙÁùºÏ²Ê from 2018 to 2022.

    His ongoing NIH-funded research aims to use AI to create personalized prenatal risk assessment tools, helping families and health care providers make informed decisions in uncertain situations. Dr. Blue has researched critical topics such as preeclampsia, preterm birth, stillbirth, and fetal growth restriction.

    As a fluent Spanish speaker, Dr. Blue enjoys working with the Spanish-speaking communities.

    Board Certification and Academic Information

    Academic Departments Obstetrics & Gynecology -Primary
    Population Health Sciences -Adjunct
    Academic Divisions Maternal Fetal Medicine
    Board Certification
    American Board of Obstetrics & Gynecology
    American Board of Obstetrics & Gynecology (Sub: Maternal-Fetal Medicine)

    Education history

    Diploma University of ¼«ËÙÁùºÏ²Ê M.S.C.I
    Maternal-Fetal Medicine - University of New Mexico School of Medicine Fellow
    Residency Obstetrics and Gynecology - Los Angeles County + USC Medical Center Resident
    Medicine - Loma Linda University School of Medicine M.D.
    Undergraduate Spanish - Pacific Union College B.A.

    Selected Publications

    Journal Article

    1. Blue NR, Allshouse AA, Moyle KA, Dimick K, Silver RM (2024). A Pilot Study of Ultrasound Assessment of Umbilical Cord and Placental Vascular Flow for Cord Accident Stillbirth Prevention. J Ultrasound Med. ()
    2. Finch A, Joss-Moore L, Allshouse A, Blue N, Haas D, Grobman WA, Parry S, Saade G, Silver RM (2024). Maternal Pre-Conception Omega-6, Omega-3, and Omega-6:Omega-3 Intake and Uterine Artery Indices in Mid-Gestation. Am J Perinatol. ()
    3. Wallace AD, Blue NR, Morgan T, Workalemahu T, Silver RM, Quinlan AR (2024). Placental somatic mutation in human stillbirth and live birth: A pilot case-control study of paired placental, fetal, and maternal whole genomes. Placenta, 154, 137-144. ()
    4. Gleason JL, Reddy UM, Chen Z, Grobman WA, Wapner RJ, Steller JG, Simhan H, Scifres CM, Blue N, Parry S, Grantz KL (2023). Comparing population-based fetal growth standards in a US cohort. Am J Obstet Gynecol. ()
    5. Yan Q, Guerrero RF, Khan RR, Surujnarine AA, Wapner RJ, Hahn MW, Raja A, Salleb-Aouissi A, Grobman WA, Simhan H, Blue NR, Silver R, Chung JH, Reddy UM, Radivojac P, Peer I, Haas DM (2023). Searching and visualizing genetic associations of pregnancy traits by using GnuMoM2b. Genetics, 225(2). ()
    6. Zimmerman RM, Hernandez EJ, Watkins WS, Blue N, Tristani-Firouzi M, Yandell M, Steinberg BA (2023). An Explainable Artificial Intelligence Approach for Discovering Social Determinants of Health and Risk Interactions for Stroke in Patients With Atrial Fibrillation. Am J Cardiol, 201, 224-226. ()
    7. Workalemahu T, Dalton S, Son SL, Allshouse A, Carey AZ, Page JM, Blue NR, Thorsten V, Goldenberg RL, Pinar H, Reddy UM, Silver RM (2023). Copy number variants and fetal structural abnormalities in stillborn fetuses: A secondary analysis of the Stillbirth Collaborative Research Network study. BJOG. ()
    8. Lueth AJ, Allshouse AA, Blue NM, Grobman WA, Levine LD, Catov J, Saade G, Yee LM, Wilson FA, Murtaugh M, Merz N, Chung J, Ray M, Scifres C, Silver RM, NIH NICHD nuMoM2b and NHLBI nuMoM2b Heart Health Study Networks (2023). Can allostatic load in pregnancy explain the association between race and subsequent cardiovascular disease risk: A cohort study. BJOG, 130(10), 1197-1206. ()
    9. Workalemahu T, Avery C, Lopez S, Blue NR, Wallace A, Quinlan AR, Coon H, Warner D, Varner MW, Branch DW, Jorde LB, Silver RM (2023). Whole-genome sequencing analysis in families with recurrent pregnancy loss: A pilot study. PLoS One, 18(2), e0281934. ()
    10. Lueth AJ, Allshouse AA, Blue NR, Grobman WA, Levine LD, Simhan HN, Kim JK, Johnson J, Wilson FA, Murtaugh M, Silver RM, for the National Institutes of Health NIH, Eunice Kennedy Shriver National Institute of Child Health and Human Development NICHD, Nulliparous Pregnancy Outcomes Study Monitoring Mothers-to-Be nuMoM2b, and National Heart, Lung, and Blood Institute NHLBI nuMoM2b Heart Health Study nuMoM2b-HHS (2022). Allostatic Load and Adverse Pregnancy Outcomes. Obstet Gynecol, 140(6), 974-982. ()
    11. Li, Z, Li, X, Zhou, H et al and 498 others, including Blue NR for the Trans-Omics for Precision Medicine TOPMed Consortium (2022). A framework for detecting noncoding rare-variant associations of large-scale whole-genome sequencing studies. Nat Methods, 19, 1599–1611.
    12. Workalemahu T, Dalton S, Allshouse A, Carey AZ, Page JM, Blue NR, Thorsten V, Goldenberg RL, Pinar H, Reddy UM, Silver RM (2022). Copy number variants and placental abnormalities in stillborn fetuses: a secondary analysis of the Stillbirth Collaborative Research Network study. BJOG, 129(13), 2125-2131. ()
    13. Bridges AG, Allshouse A, Canfield DR, Grover BW, Son SL, Einerson BD, Silver RM, Haas D, Grobman W, Simhan H, Day RC, Blue NR (2022). Association of Prostaglandin Use for Cervical Ripening with Mode of Delivery in SGA vs non-SGA Neonates. Am J Perinatol. ()
    14. Schabel MC, Roberts VHJ, Gibbins KJ, Rincon M, Gaffney JE, Streblow AD, Wright AM, Lo JO, Park B, Kroenke CD, Szczotka K, Blue NR, Page JM, Harvey K, Varner MW, Silver RM, Frias AE (2022). Quantitative longitudinal T2* mapping for assessing placental function and association with adverse pregnancy outcomes across gestation. PLoS One, 17(7), e0270360. ()
    15. Bruno A, Benson AE, Metz T, Blue NR (2022). Adjunct therapy at time of exam-indicated cervical cerclage in singleton pregnancies: a systematic review and meta-analysis. Am J Perinatol, 39(16), 1719-1725. ()
    16. Blue NR, Allshouse AA, Heerboth S, Grobman W, Mercer B, Shanks A, Bregand-White JM, Simhan H, Reddy UM, Saade G, Parry S, Silver RM (2022). Derivation and assessment of a sex-specific fetal growth standard. J Matern Fetal Neonatal Med, 35, 1-9. ()
    17. Bruno AM, Blue NR (2022). Challenges in Interpreting Obstetrics and Gynecology Literature. Clin Obstet Gynecol, 65, 225-235. ()
    18. Beck MC, Allshouse MA, Silver RM, Grobman WA, Simhan H, Haas D, Reddy UM, Blue NR (2022). High early pregnancy body mass index is associated with alterations in first and second trimester angiogenic biomarkers. Am J Obstet Gynecol MFM, 4, 100614. ()
    19. Blue NR, Mele L, Grobman WA, Bailit JL, Wapner RJ, Thorp JM Jr, Caritis SN, Prasad M, Tita ATN, Saade GR, Rouse DJ, Blackwell SC, Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units MFMU Network (2022). Predictive Performance of Newborn Small for Gestational Age by a U.S. Intrauterine versus Birth Weight-derived Standard for Short-Term Neonatal Morbidity and Mortality. Am J Obstet Gynecol MFM, 4, 100599. ()
    20. Li X, Quick C, Zhou H, and 421 others, including Blue NR for the NHLBI Trans-Omics for Precision Medicine Consortium (2022). Powerful, scalable and resource-efficient meta-analysis of rare variant associations in large whole genome sequencing studies. Nat Genet. ()
    21. Lueth A, Blue N, Silver RM, Allshouse A, Hoffman M, Grobman WA, Simhan HN, Reddy U, Haas DM (2021). Prospective evaluation of placental abruption in nulliparous women. J Matern Fetal Neonatal Med, 35, 1-8. ()
    22. Gimbel LA, Blue NR, Allshouse AA, Silver RM, Gimbel B, Grobman WA, Haas DM, Simhan HN, Mercer BM, Hatfield T (2021). Pregnancy outcomes and anxiety in nulliparous women. J Matern Fetal Neonatal Med, 35, 1-10. ()
    23. Bruno AM, Shea AE, Einerson BD, Metz TD, Allshouse AA, Scott JR, Blue NR (2021). Impact of the p-Value Threshold on Interpretation of Trial Outcomes in Obstetrics and Gynecology. Am J Perinatol, 38(12), 1223-1230. ()
    24. Blue NR, Allshouse AA, Grobman WA, Day RC, Haas DM, Simhan HN, Parry S, Saade GR, Silver RM (2021). Developing a predictive model for perinatal morbidity among small for gestational age infants. J Matern Fetal Neonatal Med, 35, 1-10. ()
    25. Bruno AM, Blue NR, Allshouse AA, Haas DM, Shanks AL, Grobman WA, Simhan H, Reddy UM, Silver RM, Metz TD (2021). Marijuana use, fetal growth, and uterine artery Dopplers. J Matern Fetal Neonatal Med, 35, 1-8. ()
    26. Blue NR, Grobman WA, Larkin JC, Scifres CM, Simhan HN, Chung JH, Saade GR, Haas DM, Wapner R, Reddy UM, Mercer B, Parry SI, Silver RM (2020). Customized versus Population Growth Standards for Morbidity and Mortality Risk Stratification Using Ultrasonographic Fetal Growth Assessment at 22 to 29 Weeks' Gestation. Am J Perinatol, 38(S 01), e46-e56. ()
    27. Bruno AM, Olmsted MW, Martin V, Einerson BD, Metz TD, Allshouse AA, Scott JR, Blue NR (2021). Rigor, reproducibility, and transparency of randomized controlled trials in obstetrics and gynecology. Am J Obstet Gynecol MFM, 3(6), 100450. ()
    28. Blue NR, Hoffman M, Allshouse AA, Grobman WA, Simhan HN, Turan OM, Parry S, Chung JH, Reddy U, Haas DM, Myers S, Mercer B, Saade GR, Silver RM (2019). Antenatal Fetal Adrenal Measurements at 22 to 30 Weeks' Gestation, Fetal Growth Restriction, and Perinatal Morbidity. Am J Perinatol, 38(7), 676-682. ()
    29. Page JM, Blue NR, Silver RM (2021). Fetal Growth and Stillbirth. Obstet Gynecol Clin North Am, 48(2), 297-310. ()
    30. Blue NR, Page JM, Silver RM (2021). Recurrence Risk of Fetal Growth Restriction: Management of Subsequent Pregnancies. Obstet Gynecol Clin North Am, 48(2), 419-436. ()
    31. Hawkins M, Parker CB, Redline S, Larkin JC, Zee PP, Grobman WA, Silver RM, Louis JM, Pien GW, Basner RC, Chung JH, Haas DM, Nhan-Chang CL, Simhan HN, Blue NR, Parry S, Reddy U, Facco F, NICHD NuMoM2b and NHLBI NuMoM2b Heart Health Study Networks (2021). Objectively assessed sleep-disordered breathing during pregnancy and infant birthweight. Sleep Med, 81, 312-318. ()
    32. Carey AZ, Blue NR, Varner MW, Page JM, Chaiyakunapruk N, Quinlan AR, Branch DW, Silver RM, Workalemahu T (2021). A systematic review to guide future efforts in the determination of genetic causes of pregnancy loss. Front Reprod Health, 3. ()
    33. Hammad IA, Blue NR, Allshouse AA, Silver RM, Gibbins KJ, Page JM, Goldenberg RL, Reddy UM, Saade GR, Dudley DJ, Thorsten VR, Conway DL, Pinar H, Pysher TJ, NICHD Stillbirth Collaborative Research Network Group (2020). Umbilical Cord Abnormalities and Stillbirth. Obstet Gynecol, 135(3), 644-652. ()
    34. Rayburn WF, Smith GA, Blue N (2019). Fetal ultrasound interpretation using a flipped learning approach during an introductory obstetrics clerkship. J Reprod Med, 64(2), 151-153. ()
    35. Blue NR, Savabi M, Beddow ME, Katukuri VR, Fritts CM, Izquierdo LA, Chao CR (2018). The Hadlock Method Is Superior to Newer Methods for the Prediction of the Birth Weight Percentile. J Ultrasound Med, 38(3), 587-596. ()
    36. Blue NR, Page JM, Silver RM (2018). Genetic abnormalities and pregnancy loss. Semin Perinatol, 43(2), 66-73. ()
    37. Blue NR, Beddow ME, Savabi M, Katukuri VR, Chao CR (2018). Comparing the Hadlock fetal growth standard to the Eunice Kennedy Shriver National Institute of Child Health and Human Development racial/ethnic standard for the prediction of neonatal morbidity and small for gestational age. Am J Obstet Gynecol, 219(5), 474.e1-474.e12. ()
    38. Blue NR, Murray-Krezan C, Drake-Lavelle S, Weinberg D, Holbrook BD, Katukuri VR, Leeman L, Mozurkewich EL (2018). Effect of ibuprofen vs acetaminophen on postpartum hypertension in preeclampsia with severe features: a double-masked, randomized controlled trial. Am J Obstet Gynecol, 218(6), 616.e1-616.e8. ()
    39. Blue NR, Beddow ME, Savabi M, Katukuri VR, Mozurkewich EL, Chao CR (2018). A Comparison of Methods for the Diagnosis of Fetal Growth Restriction Between the Royal College of Obstetricians and Gynaecologists and the American College of Obstetricians and Gynecologists. Obstet Gynecol, 131(5), 835-841. ()
    40. Weinberg D, Blue N, Holbrook B, Rayburn W (2017). Outpatient preinduction cervical ripening using a balloon catheter: A meta-analysis. J Reprod Med, 62(5), 486-492. ()
    41. Blue NR, Yordan JMP, Holbrook BD, Nirgudkar PA, Mozurkewich EL (2017). Abdominal Circumference Alone versus Estimated Fetal Weight after 24 Weeks to Predict Small or Large for Gestational Age at Birth: A Meta-Analysis. Am J Perinatol, 34(11), 1115-1124. ()
    42. Blue NR, Van Winden KR, Pathak B, Barton L, Opper N, Lane CJ, Ramanathan R, Ouzounian JG, Lee RH (2015). Neonatal Outcomes by Mode of Delivery in Preterm Birth. Am J Perinatol, 32(14), 1292-7. ()

    Editorial

    1. Silver RM, Blue NR (2021). Delivery Before 39 Weeks' Gestation for Suspected Fetal Growth Restriction: More Harm Than Good? JAMA, 326(2), 135-136. ()
    2. Blue NR, Silver RM (2021). Fetal Growth in the Twenty-First Century: A Pressing Challenge for Clinicians and Researchers. Obstet Gynecol Clin North Am, 48(2), xvii-xviii. ()